AAV-hAADC gene therapy - Agilis/National Taiwan University

Drug Profile

AAV-hAADC gene therapy - Agilis/National Taiwan University

Alternative Names: AADC deficiency gene therapy programme - Agilis; AGIL-AADC

Latest Information Update: 02 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Taiwan University
  • Developer Agilis Biotherapeutics; National Taiwan University
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn error metabolic disorders

Most Recent Events

  • 02 Dec 2016 Agilis completes a phase II trial in Inborn error metabolic disorders in Taiwan (Intracerebral) (NCT01395641)
  • 01 Dec 2016 AAV-hAADC gene therapy receives Orphan Drug status for Inborn error metabolic disorders (AADC deficiency) in European Union
  • 17 Nov 2016 AAV-hAADC gene therapy receives Rare Paediatric Disease designation for AADC deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top